Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire finally files ADHD drug Venvanse in EU

This article was originally published in Scrip

Executive Summary

An EU approval for Shire's attention-deficit hyperactivity disorder (ADHD) drug Venvanse (lisdexamfetamine dimesylate) is edging closer after the UK's medicines regulator, the MHRA agreed to act the reference member state under the decentralised procedure. The drug was first approved in the US back in February 2007 under the name Vyvanse.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC015812

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel